Date: 2013-02-28
Type of information: Plant acquisition
Acquired company: Genmab's non-plasma-derived antibody manufacturing facility (USA - Denmark)
Acquiring company: Baxter (USA -IL)
Amount: $ 10 million (€ 7.6 million)
Terms: * On February 28, 2013, Genmab has announced the signing and closing of an agreement with Baxter Healthcare Corporation for the sale of Genmab's non-plasma-derived antibody manufacturing facility, located in Brooklyn Park, Minnesota, USA, for $ 10 million. Under the terms of the agreement Genmab receives the $ 10 million (approximately DKK 57 million - € 7.6 million) in cash and Baxter acquires the facility, land, and equipment at the Brooklyn Park site. Baxter will offer employment to the 23 employees currently supporting the facility.
Details:
Related: manufacturing
bioproduction
